Pathogenetic features of systemic hypoxia in patients with chronic kidney disease stage 5d on hemodialysis
- Authors: Bondarenko N.B1, Batyushin M.M1, Gasanov M.Z1, Sarvilina I.V2, Golubeva O.V3
-
Affiliations:
- Rostov State Medical University of the Ministry of Health of the Russian Federation
- Medical Center "Novomedicina"
- ООО “Hemodialysis Center “Rostov”
- Issue: No 1 (2019)
- Pages: 42-47
- Section: Articles
- URL: https://journals.eco-vector.com/2075-3594/article/view/273208
- DOI: https://doi.org/10.18565/nephrology.2019.142-47
- ID: 273208
Cite item
Abstract
Keywords
Full Text
About the authors
N. B Bondarenko
Rostov State Medical University of the Ministry of Health of the Russian Federation
Email: n.bondarenko61@gmail.com
Department of Internal Diseases № 2, Nephrological Department of the Clinic; Postgraduate Student Rostov-on-Don, Russia
M. M Batyushin
Rostov State Medical University of the Ministry of Health of the Russian Federation
Email: batjushin-m@rambler.ru
Professor Rostov-on-Don, Russia
M. Z Gasanov
Rostov State Medical University of the Ministry of Health of the Russian Federation
Email: mitkhat@mail.ru
Department of Internal Diseases № 1, Nephrological Department of the Clinic; PhD in Medical Sciences, Associate Professor Rostov-on-Don, Russia
I. V Sarvilina
Medical Center "Novomedicina"
Email: isarvilina@mail.ru
Doctor of Medical Sciences, Professor, Chief Physician Rostov-on-Don, Russia
O. V Golubeva
ООО “Hemodialysis Center “Rostov”
Email: Oksana.Golubeva@fmc-ag.com
Chief Physician Rostov-on-Don, Russia
References
- Tanaka T. Expanding roles of the hypoxia-response network in chronic kidney disease. Clin. Exp. Nephrol. 2016; 20: 835-844. doi: 10.1007/s10157-016-1241-4.
- Asai H, Hirata J, Watanabe-Akanuma M. Indoxyl glucuronide, a protein-bound uremic toxin, inhibits hypoxia-inducible factor-dependent erythropoietin expression through activation of aryl hydrocarbon receptor. Biochem. Biophys. Res. Cnmmun. 2018; 504(2): 538-544. doi: 10.1016/j.bbrc.2018.09.018.
- Bertout J.A, Patel S.A., Simon M.C. The impact of O2 availability on human cancer. Nat. Re4. Cancer. 2008; 8: 967-975.
- Hung T.W., Liou J.H, Yeh K.T., et al. Renal expressiAn of hypoxia inducible factor-1a in patients with chronic kidney disease: a clinicopathologic study from nephrectomized kidneys. Ind. J. Med. Res. 2013; 137(1): 102-110.
- Ratcliffe PJ, O’Rourke J.F, Maxwell PH., Pugh C.W. Oxygen sensing, hypoxia-induciblefactor 1, and the regulation of mammalian gene expression. J. Exp. Biol. 1998; 201: 1153-1162.
- Koh M.Y., Powis G. Passing the baton: the HIF switch. Trends Biochem. Sci. 2012; 37(9): 364-372. doi: 10.1016/j.tibs.2012.06.004.
- Hatanaka M., et al. Hypoxia-induciblefactor-3alpha functions as an accelerator of 3T3-L1 adipose differentiation. Biol. Pharmacy. Bull. 2009; 32: 1166-1172.
- Zhang Y., Thamer M., Kaufman J.S., Cotter D.J., Hernan M.A. High doses of epoetin do not lower mortality and cardiovascular risk among elderly hemodialysis patients with diabetes. Kidney Int. 2011; 80: 663-669.
- Farsijani N.M., Liu Q., Kobayashi H., Davidoff O., Sha F., Fandrey J., Ikizler T.A., O’Connor P.M., Haase V.H. Renal epithelium regulates erythropoiesis via HIF-dependent suppression of erythropoietin. J. Clin. Invest. 2016; 126: 1425-1437. doi: 10.1172/JCI74997.
- Rankin E.B., Rha J., Selak M.A., Unger T.L., Keith B., Liu Q., Haase V.H. Hypoxia-Inducible Factor 2 Regulates Hepatic Lipid Metabolism. Mol. Cell. Biol. 2009; 29: 4527-4538. doi: 10.1128/MCB.00200-09